Intensive LOwering of BlOod low-density lipoprotein ChOlesterol with statin + ezetimibe therapy improves cardiac function after Percutaneous coronary intervention in patients with coronary stenting in Fukuoka-II (LOBOCOP-II)
Not Applicable
- Conditions
- Ischemic heart disease
- Registration Number
- JPRN-UMIN000001782
- Lead Sponsor
- Heart/vascular internal medicine,fukuoka university
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
Patients with familial hyperlipidaemia, a severe liver dysfunction (AST / ALT more than the double of the reference value), severe renal dysfunction (Cr more than 2mg/dl), diabetes mellitus inadequate control (HbA1c more than 7mg/dl), the possibility of pregnancy, and a history of hypersensitivity for the ingredient of the study drug are excluded from the study.The patients who fall under the contraindication of the study drug and the inappropriate patients by doctor's judgement are also excluded.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Evaluation of %DS by QCA(6-9 months after PCI) %DS:percent diameter stenosis QCA:quantitative coronary angiography
- Secondary Outcome Measures
Name Time Method Plaque volume by IVUS, Plaque area by MSCT, LV blood flow by the contrast echocardiography, the plaque by the carotid echo, a vascular endothelium function by FMD, the evaluation of the change of ,adhesion molecule. The measurement of blood levels of chemokine, MMP(Matrix Metalloproteinase), TIMP(Tissue Inhibitor of Metalloproteinase), adiponectine. Major adverse cardiac events (MACE) and target lesion revascularization (TLR) during follow up.